Thrivent Financial for Lutherans
FOLD

Thrivent Financial for Lutherans’s Amicus Therapeutics FOLD Stock Holding History

Thrivent Financial for Lutherans’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-29,881
Closed -$236K – 2590
2025
Q3 		$236K Sell
29,881
-25,640
-46% -$182K ﹤0.01% 2293
2025
Q2 		$318K Hold
55,521
– – ﹤0.01% 2290
2025
Q1 		$453K Buy
55,521
+44,480
+403% +$412K ﹤0.01% 2113
2024
Q4 		$104K Buy
+11,041
New +$115K ﹤0.01% 2538
2024
Q2 		– Sell
-64,999
Closed -$765K – 2543
2024
Q1 		$765K Hold
64,999
– – ﹤0.01% 2038
2023
Q4 		$922K Sell
64,999
-3,173
-5% -$36K ﹤0.01% 1890
2023
Q3 		$829K Hold
68,172
– – ﹤0.01% 1860
2023
Q2 		$856K Sell
68,172
-3,344
-5% -$39.7K ﹤0.01% 1908
2023
Q1 		$793K Buy
+71,516
New +$881K ﹤0.01% 1919
2022
Q4 		– Sell
-12,076
Closed -$126K – 2426
2022
Q3 		$126K Buy
+12,076
New +$135K ﹤0.01% 2370

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Thrivent Financial for Lutherans's FOLD Position: Q4 2025 in Review

Thrivent Financial for Lutherans sold out of Amicus Therapeutics (FOLD) in Q4 2025, closing a stake of 29,881 shares — an estimated $236K sold.

Thrivent Financial for Lutherans first reported a position in FOLD in Q3 2022 and held it in 10 quarters. The position peaked at $922K in Q4 2023. 332 funds tracked by Wall St. Rank hold FOLD as of Q4 2025.

  • Thrivent Financial for Lutherans reported no remaining Amicus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 29,881 Amicus Therapeutics shares in Q4 2025, an estimated $236K.
  • Thrivent Financial for Lutherans first reported a position in Amicus Therapeutics in Q3 2022 and held it in 10 quarters.
  • Thrivent Financial for Lutherans's Amicus Therapeutics position peaked at $922K in Q4 2023.
  • 332 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2025.

Based on Thrivent Financial for Lutherans's 13F filing for Q4 2025, filed 5 Feb 2026.